Rapid Micro Biosystems® Announces Publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology
LOWELL, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company, providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology.
- LOWELL, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company, providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology.
- This study, published online by the PDA Journal of Pharmaceutical Science and Technology, sought to evaluate colony counters as an automated compendial microbiological test method and references current regulatory guidelines.
- In order to simplify validation, all sites followed a modular validation approach that had been developed by the participants.
- The modular validation facilitates the efficient implementation of the technology to routine use while complying with regulatory requirements.